Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

Showing results for "1"

Sub-Project Summary

An outline of ORIGINS sub-projects by name

News & Events

Triage phone service

A reminder we have updated our Phone Triage System and provided a triage helpful tips sheet for all families to access.

News & Events

Developing a pencil grasp

In this blog, Senior Occupational Therapist Gayle Hillen explores the steps to developing a functional pencil grasp.

News & Events

Looking at autism through a social model

In​ this blog, Speech Pathologist Linda Arabi discusses the social model and how it influences the supports we provide to autistic children and their families.

News & Events

CliniSibs - Group Sibling Program

We are excited to announce we will be offering CliniSibs, a sibling therapy group designed to assist and support siblings of a child with autism.

News & Events

Embrace Big Idea 2023 winners announced

Photo (clockwise from top-left): Dr Craig Taplin, Mx Rigel Paciente, Ms Heather Roby, Dr Keely Bebbington, Dr Alix Woolard.

Research

Wellbeing study

Burns are a common cause of emergency presentations, and most burn injuries happen to children and adolescents.

Research

Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma

Medulloblastoma (MB) consists of four core molecular subgroups with distinct clinical features and prognoses. Treatment consists of surgery, followed by radiotherapy and cytotoxic chemotherapy. Despite this intensive approach, outcome remains dismal for patients with certain subtypes of MB, namely, MYC-amplified Group 3 and TP53-mutated SHH. Using high-throughput assays, six human MB cell lines were screened against a library of 3208 unique compounds. We identified 45 effective compounds from the screen and found that cell cycle checkpoint kinase (CHK1/2) inhibition synergistically enhanced the cytotoxic activity of clinically used chemotherapeutics cyclophosphamide, cisplatin, and gemcitabine.

Research

Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia

Our population-based cohort study demonstrates that >90% coverage in the first year of a universal 3 + 0 PCV program provided high population-level protection

Research

The rare and undiagnosed diseases diagnostic service – application of massively parallel sequencing in a state-wide clinical service

The Rare and Undiagnosed Diseases Diagnostic Service refers to a genomic diagnostic platform operating within the Genetic Services of Western Australia